Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT4 | P35916 | 3/20 | 0.51 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 7/20 | 0.47 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22545899 | 1.00 | FLT4 (0.51) | FLT4MAPK6JAK3CDK4CCNA2 | |
| SCHEMBL22544617 | 0.93 | MAP4K1 (0.49) | JAK3CDK4CDK2CDK6IGF1R | |
| SCHEMBL22097868 | 0.89 | FLT4 (0.52) | FLT4MAPK6JAK3IGF1RKDR | |
| SCHEMBL31557686 | 0.89 | FLT4 (0.52) | FLT4MAPK6JAK3IGF1RKDR | |
| SCHEMBL22544640 | 0.88 | JAK3 (0.55) | JAK3 | |
| SCHEMBL30956461 | 0.88 | FLT4 (0.55) | FLT4MAPK6JAK3IGF1RKDR | |
| SCHEMBL29754222 | 0.87 | CDK4 (0.54) | FLT4MAPK6JAK3CDK4CCNA2 | |
| SCHEMBL22544564 | 0.87 | CDK4 (0.54) | FLT4MAPK6JAK3CDK4CCNA2 | |
| SCHEMBL24853210 | 0.87 | IGF1R (0.51) | FLT4MAPK6JAK3IGF1RKDR | |
| SCHEMBL27169578 | 0.86 | FLT4 (0.48) | FLT4MAPK6JAK3CDK4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK3, JAK1, JAK2 | FLT4 727/4885MAPK6 557/4885JAK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.